<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - CO-AMOXICLAV</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>CO-AMOXICLAV</h1>

        <p><a href="../drugClass/PHP34546.html">PENICILLINS</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#professionSpecificInformation" data-toggle="tab">Profession specific information</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Infections due to beta-lactamase-producing strains (where amoxicillin alone not appropriate), including respiratory tract infections, bone and joint infections, genito-urinary and abdominal infections, cellulitis and animal bites</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                250/125 mg every 8 hours; (by mouth) increased to 500/125 mg every 8 hours, increased dose used for severe infection.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                1.2 g every 8 hours, intravenous injection to be administered over 3&#8211;4 minutes.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                250/125 mg every 8 hours; (by mouth) increased to 500/125 mg every 8 hours, increased dose used for severe infection.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Severe dental infection with spreading cellulitis</span>,
                <span class="indication">Dental infection not responding to first-line bacterial</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using tablets</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                250/125 mg every 8 hours for 5 days.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                250/125 mg every 8 hours for 5 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Surgical prophylaxis</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1.2 g, to be administered up to 30 minutes before the procedure, then 1.2 g every 8 hours for up to 2&#8211;3 further doses in high risk procedures.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>Doses are expressed as co-amoxiclav.</p><p>A mixture of amoxicillin (as the trihydrate or as the sodium salt) and clavulanic acid (as potassium clavulanate); the proportions are expressed in the form x/y where x and y are the strengths in milligrams of amoxicillin and clavulanic acid respectively.</p>
            </section>
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Not known to be harmful.</p>
            </section>
      </section>


      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in adults</h3>
              <p>
            <i>Co-amoxiclav 250/125 tablets or 500/125 tablets</i>: if eGFR 10&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>, one <i>250/125</i> strength tablet every 12 hours or one <i>500/125</i> strength tablet every 12 hours; if eGFR less than 10&#8239;mL/minute/1.73&#8239;m<sup>2</sup>, one <i>250/125</i> strength tablet every 24 hours or one <i>500/125</i> strength tablet every 24 hours.</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>
            <i>Co-amoxiclav injection</i> (expressed as co-amoxiclav): if eGFR 10&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>, 1.2&#8239;g initially, then 600&#8239;mg every 12 hours; if eGFR less than 10&#8239;mL/minute/1.73&#8239;m<sup>2</sup>, 1.2&#8239;g initially, then 600&#8239;mg every 24 hours.</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>
            <i>Co-amoxiclav 125/31 suspension</i>, <i>250/62 suspension, 250/125 tablets, or 500/125 tablets</i>: use normal dose every 12 hours if estimated glomerular filtration rate 10&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>. Use the normal dose recommended for mild or moderate infections every 12 hours if estimated glomerular filtration rate less than 10&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>
            <i>Co-amoxiclav injection</i>: use normal initial dose and then use half normal dose every 12 hours if estimated glomerular filtration rate 10&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; use normal initial dose and then use half normal dose every 24 hours if estimated glomerular filtration rate less than 10&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
        
            <section class="generalInformation">
              <p>Risk of crystalluria with high doses (particularly during parenteral therapy).</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Accumulation of electrolytes contained in parenteral preparations can occur in patients with renal failure.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in adults</h3>
              <p>
            <i>Co-amoxiclav 400/57 suspension</i>: avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>
            <i>Co-amoxiclav 400/57 suspension</i>: avoid if estimated glomerular filtration rate less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>History of co-amoxiclav-associated jaundice or hepatic dysfunction</li>
            <li>history of penicillin-associated jaundice or hepatic dysfunction</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Cholestatic jaundice, hepatitis, nausea, vomiting,
              </p>
              <p>
                <strong>rare:</strong> Dizziness, headache, prolongation of bleeding time,
              </p>
              <p>
                <strong>notKnown:</strong> Exfoliative dermatitis, Steven-Johnson syndrome, toxic epidermal necrolysis, vasculitis,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>rare:</strong> phlebitis at injection site, superficial staining of teeth with suspension,
              </p>
        
            <section class="advice">
                <h3>Rash</h3>
              <p>If rash occurs, discontinue treatment.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For <i>intravenous infusion</i>, dilute reconstituted solution to a concentration of 10&#8239;mg/mL with Sodium Chloride 0.9%; give intermittently over 30&#8211;40 minutes.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>intravenous infusion</i> (<i>Augmentin</i>
            <tm tmtype="reg"/>), give intermittently <i>in</i> Sodium chloride 0.9%. Reconstitute 600&#8239;mg initially with 10&#8239;mL water for injections, then dilute with 50&#8239;mL infusion fluid; reconstitute 1.2&#8239;g initially with 20&#8239;mL water for injections, then dilute with 100&#8239;mL infusion fluid; give over 30&#8211;40 minutes</p><p>
            <i>via</i> drip tubing <i>in</i> Sodium chloride 0.9%.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Co-amoxiclav for bacterial infections</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/co-amoxiclav-bacterial-infections-0">www.medicinesforchildren.org.uk/co-amoxiclav-bacterial-infections-0</xref>
            </p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Acute lymphocytic leukaemia (increased risk of erythematous rashes)
          </li>
          <li>
            chronic lymphocytic leukaemia (increased risk of erythematous rashes)
          </li>
          <li>
            cytomegalovirus infection (increased risk of erythematous rashes)
          </li>
          <li>
            glandular fever (erythematous rashes common)
          </li>
          <li>
            maintain adequate hydration with high doses (particularly during parental therapy)
          </li>
        </ul>
        <ul>
          <li>
              <strong>With intravenous use:</strong>
            accumulation of electrolytes contained in parenteral preparations can occur with high doses
          </li>
        </ul>
        <ul>
          <li>
            <p>Cholestatic jaundice can occur either during or shortly after the use of co-amoxiclav. An epidemiological study has shown that the risk of acute liver toxicity was about 6 times greater with co-amoxiclav than with amoxicillin. Cholestatic jaundice is more common in patients above the age of 65 years and in men; these reactions have only rarely been reported in children. Jaundice is usually self-limiting and very rarely fatal. The duration of treatment should be appropriate to the indication and should not usually exceed 14 days.</p>
          </li>
        </ul>
      </section>




      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Doses are expressed as co-amoxiclav: a mixture of amoxicillin (as the trihydrate or as the sodium salt) and clavulanic acid (as potassium clavulanate); the proportions are expressed in the form x/y where x and y are the strengths in milligrams of amoxicillin and clavulanic acid respectively.</p>
            </section>
            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Flavours of oral liquid formulations may include raspberry and orange.</p>
            </section>
      </section>






      <section class="tab-pane" id="professionSpecificInformation">
        <h2>Profession specific information</h2>

          <h3>Dental practitioners</h3>
        
            <section class="dentalPractitionersFormulary">
              <p>Co-amoxiclav 250/125 Tablets may be prescribed.</p><p>Co-amoxiclav 125/31 Suspension may be prescribed.</p><p>Co-amoxiclav 250/62 Suspension may be prescribed.</p>
            </section>
      </section>



      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of CO-AMOXICLAV</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            infusion,

            <div id="PHP76352"><a href="../medicinalForm/PHP76352.html" data-target="#PHP76352" data-action="load">Tablet</a></div>
            <div id="PHP76373"><a href="../medicinalForm/PHP76373.html" data-target="#PHP76373" data-action="load">Oral suspension</a></div>
            <div id="PHP76366"><a href="../medicinalForm/PHP76366.html" data-target="#PHP76366" data-action="load">Powder for solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
